Literature DB >> 21494937

[Skin manifestations in lupus erythematosus: clinical aspects and therapy].

A Kuhn1, V Ruland, G Bonsmann.   

Abstract

Lupus erythematosus (LE) is an inflammatory autoimmune disorder, which is characterized by clinically heterogeneous manifestations of different organs. In systemic LE (SLE) the skin, the musculoskeletal system, the kidneys, the cardiovascular and central nervous systems can be involved. The skin lesions can be divided into LE-specific and LE-non-specific manifestations, the former represent the subtypes of cutaneous LE (CLE). The diagnosis is confirmed by clinical, histopathological, immunoserological and genetic features. The treatment is similar for the different subtypes of CLE; however, the therapeutic regimen should be individually defined in each patient. Antimalarials are still the first-line systemic therapy and in addition to sunscreens, glucocorticosteroids and calcineurin inhibitors have an important impact as topical agents in this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494937     DOI: 10.1007/s00393-011-0789-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  44 in total

1.  Phototesting in lupus erythematosus: a 15-year experience.

Authors:  A Kuhn; M Sonntag; D Richter-Hintz; C Oslislo; M Megahed; T Ruzicka; P Lehmann
Journal:  J Am Acad Dermatol       Date:  2001-07       Impact factor: 11.527

2.  Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine.

Authors:  T Ruzicka; C Sommerburg; G Goerz; P Kind; H Mensing
Journal:  Br J Dermatol       Date:  1992-11       Impact factor: 9.302

Review 3.  The 100th anniversary of lupus erythematosus tumidus.

Authors:  Annegret Kuhn; Dennis Bein; Gisela Bonsmann
Journal:  Autoimmun Rev       Date:  2009-01-20       Impact factor: 9.754

4.  Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.

Authors:  M L Jewell; D P McCauliffe
Journal:  J Am Acad Dermatol       Date:  2000-06       Impact factor: 11.527

5.  A serology-based approach combined with clinical examination of 125 Ro/SSA-positive patients to define incidence and prevalence of subacute cutaneous lupus erythematosus.

Authors:  Karin Popovic; Fredrik Nyberg; Marie Wahren-Herlenius; Filippa Nyberg
Journal:  Arthritis Rheum       Date:  2007-01

6.  Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study.

Authors:  Annegret Kuhn; Kristina Gensch; Merle Haust; Anna-Maria Meuth; France Boyer; Patrick Dupuy; Percy Lehmann; Dieter Metze; Thomas Ruzicka
Journal:  J Am Acad Dermatol       Date:  2011-01       Impact factor: 11.527

Review 7.  Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus.

Authors:  A Kuhn; V Ruland; G Bonsmann
Journal:  Lupus       Date:  2010-08       Impact factor: 2.911

Review 8.  Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT).

Authors:  T Yoshimasu; A Hiroi; K Uede; F Furukawa
Journal:  Eur J Dermatol       Date:  2001 Jan-Feb       Impact factor: 3.328

9.  A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus.

Authors:  G B E Jemec; S Ullman; M Goodfield; A Bygum; A B Olesen; J Berth-Jones; F Nyberg; M Cramers; J Faergemann; P Andersen; A Kuhn; T Ruzicka
Journal:  Br J Dermatol       Date:  2009-06-05       Impact factor: 9.302

Review 10.  The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination.

Authors:  D J Wallace
Journal:  Semin Arthritis Rheum       Date:  1989-05       Impact factor: 5.532

View more
  2 in total

Review 1.  The Diagnosis and Treatment of Systemic Lupus Erythematosus.

Authors:  Annegret Kuhn; Gisela Bonsmann; Hans-Joachim Anders; Peter Herzer; Klaus Tenbrock; Matthias Schneider
Journal:  Dtsch Arztebl Int       Date:  2015-06-19       Impact factor: 5.594

2.  [Rheumatic diseases with primary onset in young adults: spondyloarthritis and connective tissue diseases].

Authors:  R Max; N Blank; H M Lorenz
Journal:  Internist (Berl)       Date:  2012-09       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.